GPT and neoplasm: With a ~40-fold difference in binding affinity, HAV- and LAV-ADCs showed comparable rates and degrees of tumor regression activity (at equivalent doses); however, the reduced affinity of the LAV-ADC led to an improved liver toxicity profile with no overt changes in liver function tests (AST and ALT).